Background The aims of this study were to determine the incidence of tuberculosis (TB) and
nontuberculous mycobacteria (NTM) lung disease in patients who were treated with tumor …

Methods Patients with TB detected within 12 months of the initiation of TNF-α inhibitor
treatment were included, if seen from January 1, 2000 to August 31, 2011. We …

Background We aimed to investigate the results of anti-tumor necrosis factor (TNF) therapy
in patients with a previous history of tuberculosis (TB). Methods A total of 101 patients with a …

Rationale: Current guidelines recommend that all patients undergoing treatment with a
tumor necrosis factor-α antagonist should receive screening for latent tuberculosis and …

The objective of this study is to estimate the incidence of active tuberculosis in patients with
inflammatory diseases receiving tumor necrosis factor-alpha (TNF-α) antagonists and to …

Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-
tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes …

Purpose Anti-tumor necrosis factor-alpha (TNF-α) medications represent a major
advancement in the management of chronic inflammatory diseases. However, these agents …

Aim The aim of this study was to investigate the incidence of tuberculosis (TB) following anti‐
tumor necrosis factor (TNF) therapy in an intermediate TB burden area and to compare the …

Objectives To evaluate the characteristics of patients who developed tuberculosis while
receiving tumor necrosis factor‐alpha (TNF‐α) antagonists and the related factors with …

Background: Tumor necrosis factor (TNF)-α inhibitors are known to increase the risk of
tuberculosis (TB). Objectives: To examine the factors associated with an increased risk of TB …